FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2180-2183 November 22, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Barter, P. J. PubMed Citation

Raising plasma levels of high-density lipoprotein (HDL) cholesterol has been a therapeutic goal ever since the strong inverse association between HDL levels and the risk of coronary heart disease was first observed.¹ Nearly two decades ago, the discovery that persons in Japan had extremely high levels of HDL cholesterol because of a genetic deficiency involving the cholesteryl ester transfer protein (CETP) led to the concept that pharmacologic inhibition of CETP could raise HDL cholesterol levels. When this theory proved to be true in humans, it led to great anticipation that CETP inhibition would permit the ultimate test of the "HDL . . . [Full Text of this Article]

Source Information

From the University of Pennsylvania School of Medicine, Philadelphia.

This article (10.1056/NEJMe0707210) was published at www.nejm.org on November 5, 2007.

Related Letters:

Torcetrapib and Coronary Events
Lackner K. J., Cohn L. J., Dullaart R. P., Kobold A. C. M., van Tol A., Barter P., Shear C. L., Revkin J. H., Rader D. J.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1862-1864, Apr 24, 2008. Correspondence

This article has been cited by other articles:

• Thompson, A., Di Angelantonio, E., Sarwar, N., Erqou, S., Saleheen, D., Dullaart, R. P. F., Keavney, B., Ye, Z., Danesh, J. (2008). Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA 299: 2777-2788 [Abstract] [Full Text]  
• deGoma, E. M., deGoma, R. L., Rader, D. J. (2008). Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.. J Am Coll Cardiol 51: 2199-2211 [Abstract] [Full Text]  
• Wild, S., Byrne, C. D (2008). Time to rethink high-density lipoprotein?. Heart 94: 692-694 [Full Text]  
• Movva, R., Rader, D. J. (2008). Laboratory Assessment of HDL Heterogeneity and Function. Clin. Chem. 54: 788-800 [Abstract] [Full Text]  
• Lackner, K. J., Cohn, L. J., Dullaart, R. P., Kobold, A. C. M., van Tol, A., Barter, P., Shear, C. L., Revkin, J. H., Rader, D. J. (2008). Torcetrapib and Coronary Events. NEJM 358: 1862-1864 [Full Text]  
• DeMaria, A. N. (2008). Clinical trials and clinical judgment.. J Am Coll Cardiol 51: 1120-1122 [Full Text]